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論 文 内 容 の 要 旨 
 Systemic lupus erythematosus (SLE) is a systemic autoimmune disease, which includes dysregulation of 
immune systems and various autoimmune disorders resulting in multi-organ injury.  Lupus nephritis is a 
typical symptom and one of the most severe organ disorders associated with SLE.  It is found in about 50% of 
patients and has a major impact on prognosis, however, there are few reliable marker for lupus nephritis other 
than urinalysis.  Another typical feature of SLE is production of autoantibodies such as anti-double-stranded 
DNA antibody.  Deposition of autoantibodies and immune complex causes renal injury.  In clinical practice, 
autoantibodies are useful for the diagnosis of autoimmune diseases as well as for prognosis and evaluation of 
disease activities.  In SLE, analysis of autoantigens was not performed by proteome scale.  Therefore, we 
screened for novel autoantibodies associated with SLE, particularly lupus nephritis by proteomic approaches 
described below. 
 We used human umbilical vein endothelial cell protein extracts as the object of autoantigen screening, because 
vasculitis is one of the clinical symptoms in SLE patients.  Extracted proteins were separated by two 
dimensional-polyacrylamide gel electrophoresis.  To detect autoantigens, western blotting was performed using 
sera from SLE patients and healthy controls.  By western blotting, positive spots only detected in SLE patients’ 
sera were considered possible autoantigens, and these proteins were identified by LC-MS/MS analysis. 
 In this study, we detected several autoantigens by proteomic approach.  One of the identified novel 
autoantigen was aldolase A, which is known as a glycolytic enzyme.  To investigate the anti-aldolase A 
antibodies, we performed ELISA analysis.  Anti-aldolase A antibodies were detected in SLE (29.3%), 
rheumatoid arthritis (RA) (8.2%) and absent in healthy control.  In SLE patients suffering nephritis, 43.4% 
were positive for anti-aldolase A autoantibodies, which was significantly higher than the prevalence for those 
without nephritis (11.1%).  Although anti-aldolase A antibodies were detected in RA patients’ sera as previously 
reported, we found that the epitope regions were different from SLE by western blotting using various deletion 
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mutants.  Therefore, these results indicate that autoantibodies against aldolase A may serve as an alternative 
clinical biomarker of SLE associated with nephritis, and epitope regions were useful to distinguish SLE and RA. 
論 文 審 査 の 結 果 の 要 旨 
 全身性エリテマトーデス（SLE）において様々な自己抗体が見られるが、臨床上、抗 Sm 抗体等が診断に用いられ
ている。しかし、抗 Sm 抗体は感度が低いため、より感度の高い自己抗体や臨床症状に相関したマーカーとなる自己
抗体の同定が望まれている。学位申請者は、２次元電気泳動法と SLE 患者血清を用いた Western Blot 法を組み合わ
せたプロテオミクス手法により、新規自己抗原のスクリーニングを行い、aldolase A を同定した。そして、ELISA 法
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